TL-895 是一种有效的，具有口服活性的，ATP 竞争性的，高度选择性不可逆 BTK 抑制剂，其 IC50 和 Ki 值分别为 1.5 nM 和 11.9 nM。TL-895 可用于 JAKi 复发/难治性骨髓纤维化、急性髓系白血病、COVID-19 和癌症研究。
| Cas No. | 1415823-49-2 |
| 分子式 | C25H26FN5O2 |
| 分子量 | 447.5 |
| 溶解度 | DMSO : 250 mg/mL (558.66 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively[1]. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research[2][3][4]. [1]. Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655.
[2]. Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci
[3]. A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
[4]. Study of TL-895 in Subjects With Myelofibrosis |
